AI Article Synopsis
- * TLR2 ligands, used as adjuvants in the Haemophilus influenzae type B vaccine, can enhance human mucosal B cell differentiation and support significant immune responses.
- * The study shows that TLR2 stimulation increases specific B cell markers and antibody production, indicating that TLR2-ligand vaccines could effectively promote mucosal immunity, even if not directly administered through mucosal routes.
Article Abstract
There is a need for developing vaccines that elicit mucosal immunity. Although oral or nasal vaccination methods would be ideal, current strategies have yielded mixed success. Toll-like receptor 2 (TLR2) ligands are effective adjuvants and are currently used in the Haemophilus influenzae type B vaccine. Induction of humoral immunity in the mucosa is critical for effective vaccination; thus, we sought to determine the effects of TLR2 ligands on human mucosal B cell differentiation. We demonstrate that TLR2 ligands induce CCR9 and CCR10 expression by circulating B cells and increased chemotaxis to cognate chemokines CCL25 and CCL28 suggesting that TLR2 induces B cell homing to the gastrointestinal tract. TLR2 stimulation of B cells also induced J chain and IgA production demonstrating the induction of mucosal-like antibody secreting cells. These observations suggest that vaccines containing TLR2-ligands as adjuvants could induce mucosal B cell immunity even when delivered in a non-mucosal manner.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clim.2010.09.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!